Joshua Berlin is a Dermatology physician. OpenAlex indexes 31 publications with 461 citations (h-index 11); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10383 Hagen Ranch Rd Ste 100
Boynton Beach, FL 33437
Telephone
561-739-5252Registry record last updated 2 Jul 2018.
Clinical trials
- A Novel Combination Oral Agent to Treat Acne Vulgaris
Sponsor: Nexgen Dermatologics, Inc.
- A Novel Oral Natural Extract for the Treatment of Senile Purpura
Sponsor: Nexgen Dermatologics, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20257 payments
- Arcutis Biotherapeutics, Inc.Program year20254 payments
- Organon LLCProgram year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
29.9%Azole Antifungal15.9%Ketoconazole100%Part D≥260 patientsTetracycline-class Drug3.9%Doxycycline Hyclate100%Part D≥92 patients+ 5 more classes in this area
Respiratory
25.9%Corticosteroid14.2%Mometasone Furoate100%Part D≥252 patientsRNA Synthetase Inhibitor Antibacterial11.6%Mupirocin100%Part D≥243 patientsSensory organs
24%Corticosteroid22.1%Hydrocortisone53%Clobetasol Propionate35%Betamethasone Dipropionate6%Desonide6%Part D≥228 patientsAminoglycoside Antibacterial1.9%Gentamicin Sulfate100%Part D≥47 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Critical Considerations on Optimizing Topical Corticosteroid Therapy
PubMed Central
2015 - [Not Available].
PubMed
2015
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”